Sanofi disclosed its total number of issued shares and voting rights as of May 31, 2026. The company has issued 1,214,099,027 shares, with 1,333,575,416 real voting rights excluding treasury shares, and a theoretical total of 1,349,603,933 voting rights including treasury shares. This update is part of regulatory compliance under French commercial and stock market laws. Investors can access this information on Sanofi's official website for transparency and governance purposes.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
